Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication ofHelicobacter pyloriin Peptic Ulcer Disease.
OBJECTIVE
The resistance rate ofHelicobacter pyloriis gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-lineH. pylorieradication in peptic ulcer disease.


METHODS
Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-lineH. pylorieradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed.


RESULTS
The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/gastroduodenal ulcer, 68.8%, p=0.655).


CONCLUSIONS
Levofloxacin-based third-lineH. pylorieradication showed efficacy similar to that of previously reported first/second-line therapies.
Department of Internal Medicine, Seoul National University Hospital, Healthcare System Gangnam Center, Healthcare Research Institute, Seoul, Korea.|Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Joo Hyun
JH
Lim
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Sang Gyun
SG
Kim
Department of Internal Medicine, Seoul National University Hospital, Healthcare System Gangnam Center, Healthcare Research Institute, Seoul, Korea.
Ji Hyun
JH
Song
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Jae Jin
JJ
Hwang
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Dong Ho
DH
Lee
Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
Jae Pil
JP
Han
Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
Su Jin
SJ
Hong
Department of Internal Medicine, Inje University College of Medicine, Busan, Korea.
Ji Hyun
JH
Kim
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Seong Woo
SW
Jeon
Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Gwang Ha
GH
Kim
Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
Ki-Nam
KN
Shim
Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
Woon Geon
WG
Shin
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Bucheon, Korea.
Tae Ho
TH
Kim
Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
Sun Moon
SM
Kim
Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
Il-Kwon
IK
Chung
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Hyun-Soo
HS
Kim
Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
Heung Up
HU
Kim
Medical Research Collaborating Center, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea.
Joongyub
J
Lee
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Jae Gyu
JG
Kim
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D064704:Levofloxacin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; D064704:Levofloxacin
Helicobacter pylori; Levofloxacin; Third-line eradication